Enzo Biochem Applies for Listing Shares On the New York Stock Exchange; Trading Scheduled to Start Week of December 13, 1999.

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Dec. 8, 1999--

Enzo Biochem, Inc. (ASE:ENZ), today announced that it has filed an application to list its common stock on the New York Stock Exchange (NYSE). The company expects its shares will commence trading on the NYSE under the symbol "ENZ" during the week of December 13, 1999.

"Enzo is a leading biotechnology company specializing in gene identification and gene regulation technologies for diagnostic and therapeutic applications. Given the profitable growth of our Company and the broadening interest in its common stock, listing of Enzo's shares on the New York Stock Exchange, the largest and most prestigious auction market, is a major development in our Company's history," said Barry Weiner, President. "We expect this move to be of significant benefit as we continue to grow Enzo."

"In the relatively short 20-year history of Enzo Biochem, the Company has demonstrated an impressive ability to develop new diagnostic tools for the healthcare industry and to formulate new proprietary treatments that are charting new biotechnological approaches to treating disease," said Richard A. Grasso, Chairman and CEO of the New York Stock Exchange. "It is a privilege to welcome Enzo Biochem to the family of the New York Stock Exchange companies, particularly since the Company joins a growing roster of renowned technology companies that are benefiting all of mankind and which now trade on the Exchange."

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Its proprietary research products, chiefly proprietary gene labeling reagents with approximately 200 patents worldwide, are sold to the medical research and gene sequencing markets throughout the world. The Company's therapeutic division is conducting two human clinical trials, one for HIV-infected patients and one for patients infected with hepatitis B virus. Other therapeutic applications of Enzo's proprietary technology are directed towards the treatment of cholesterol management, inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and diabetes.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.